Display Settings:

Format

Send to:

Choose Destination

    Fertil Steril. 2008 Oct;90(4):1197.e1-4. Epub 2008 Jan 28.

    Therapeutic response to metformin in an underweight patient with polycystic ovarian syndrome.

    Al-Ozairi E, Quinton R, Advani A.

    Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom.

    OBJECTIVE: To report a case where insulin sensitization restored menses in an underweight woman with polycystic ovarian syndrome (PCOS). DESIGN: Case report. SETTING: Tertiary care center. PATIENT(S): A 19-year-old woman with a body mass index of 16.9 kg/m(2), severe hirsutism, and oligomenorrhea. INTERVENTION(S): Insulin sensitization with metformin. MAIN OUTCOME MEASURE(S): Impact of metformin therapy on menstrual cycle and serum T and fasting insulin levels. RESULT(S): Metformin, without weight loss or increased physical activity, resulted in restoration of menstrual cycle, reduction in serum T, and improvement in insulin resistance (IR). CONCLUSION(S): This case highlights the contribution of PCOS-related IR, distinct from visceral adiposity, and demonstrates the effectiveness of pharmacological insulin-sensitization independent of weight loss or lifestyle adjustments.

    PMID: 18222436 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read Click here to read Click here to read

    Patient drug information

    • Metformin (Fortamet®, Glucophage®, Glucophage® XR, ...)

      Metformin is used alone or with other medications, including insulin, to treat type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood) ....